iScience,
Journal Year:
2023,
Volume and Issue:
26(4), P. 106409 - 106409
Published: March 16, 2023
BCL-2-like
protein
1
(BCL2L1)
is
a
key
component
of
cell
survival
and
death
mechanisms.
Its
dysregulation
altered
ratio
splicing
variants
associate
with
pathologies.
However,
isoform-specific
loss-of-function
analysis
BCL2L1
remains
unexplored.
Here
we
show
the
functional
impact
genetically
inhibiting
Bcl-x
short-isoform
(Bcl-xS)
in
vivo.
Bcl-xS
expressed
most
tissues
predominant
expression
spleen
blood
cells
mice.
knockout
(KO)
mice
no
overt
abnormality
until
3
months
age.
Thereafter,
KO
develop
cardiac
hypertrophy
contractile
dysfunction
splenomegaly
by
6
months.
Cardiac
fibrosis
significantly
increases
KO,
but
frequency
apoptosis
indistinguishable
despite
cardiomyopathy.
The
Akt/mTOR
JNK/cJun
signaling
are
upregulated
male
heart,
activated
increased
Bax
spleen.
These
results
suggest
that
may
be
dispensable
for
development
essential
maintaining
homeostasis
multiple
organs.
Cell Death and Disease,
Journal Year:
2023,
Volume and Issue:
14(4)
Published: April 6, 2023
Abstract
Cyclin
D1
(CCND1),
a
crucial
mediator
of
cell
cycle
progression,
possesses
many
mutation
types
with
different
frequencies
in
human
cancers.
The
G870A
is
the
most
common
CCND1
,
which
produces
two
isoforms:
full-length
CCND1a
and
divergent
C-terminal
CCND1b.
dysregulation
isoforms
associated
multiple
Exploring
molecular
mechanism
has
offer
new
insight
for
cancer
treatment.
On
this
basis,
alterations
gene
are
described,
including
amplification,
overexpression,
mutation,
especially
mutation.
Subsequently,
we
review
characteristics
caused
by
Additionally,
summarize
cis-regulatory
elements,
trans-acting
factors,
splice
involved
splicing
regulation
CCND1.
Furthermore,
highlight
function
cycle,
invasion,
metastasis
Importantly,
clinical
role
also
discussed,
particularly
concerning
prognosis,
chemotherapy,
radiotherapy.
Last,
emphasis
given
to
corrective
strategies
that
modulate
cancerous
isoforms.
Thus,
it
highlighting
significance
aberrant
as
targets
therapy.
Clinical and Translational Medicine,
Journal Year:
2023,
Volume and Issue:
13(10)
Published: Oct. 1, 2023
Background
N6-methyladenosine
(m6A),
the
most
prevalent
internal
mRNA
modification
in
eukaryotes,
is
added
by
m6A
methyltransferases,
removed
demethylases
and
recognised
m6A-binding
proteins.
This
significantly
influences
carious
facets
of
RNA
metabolism
plays
a
pivotal
role
cellular
physiological
processes.
Main
body
Pre-mRNA
alternative
splicing,
process
that
generates
multiple
splice
isoforms
from
multi-exon
genes,
contributes
to
protein
diversity
mammals.
Moreover,
presence
crosstalk
between
with
modifications
on
pre-mRNAs
exerting
regulatory
control,
has
been
established.
The
modulates
splicing
patterns
recruiting
specific
RNA-binding
proteins
(RBPs)
regulate
or
directly
influencing
interaction
RBPs
their
target
RNAs.
Conversely,
can
impact
deposition
recognition
mRNAs.
integration
expanded
scope
therapeutic
strategies
for
cancer
treatment,
while
offers
novel
insights
into
mechanistic
methylation
initiation
progression.
Conclusion
review
aims
highlight
biological
functions
machinery
its
implications
tumourigenesis.
Furthermore,
we
discuss
clinical
relevance
understanding
m6A-dependent
tumour
therapies.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Sept. 6, 2023
The
treatment
of
cancer
was
revolutionized
within
the
last
two
decades
by
utilizing
mechanism
immune
system
against
malignant
tissue
in
so-called
immunotherapy.
Two
main
developments
boosted
immunotherapy:
1)
use
checkpoint
inhibitors,
which
are
characterized
a
relatively
high
response
rate
mainly
solid
tumors;
however,
at
cost
serious
side
effects,
and
2)
chimeric
antigen
receptor
(CAR)-T
cells,
were
shown
to
be
very
efficient
hematologic
malignancies,
but
failed
show
clinical
effectiveness
tumors
until
now.
In
addition,
active
immunization
individual
is
emerging,
first
products
have
reached
approval.
These
new
options
cost-intensive
not
financially
compensated
health
insurance
many
countries.
Hence,
strategies
must
developed
make
immunotherapy
affordable
improve
cost-benefit
ratio.
this
review,
we
discuss
following
strategies:
leverage
antigenicity
“cold
tumors”
with
reagents,
microbiome-based
as
markers
or
therapeutics,
3)
apply
measures
that
adoptive
cell
therapy
(ACT)
cheaper,
e.g.,
off-the-shelf
products,
4)
immunotherapies
offer
cheaper
platforms,
such
RNA-
peptide-based
vaccines
shared
common
antigens
instead
highly
personal
antigens,
5)
small
set
predictive
biomarkers
“sequence
everything”
approach,
6)
explore
immunohistochemistry
may
direct
therapies.
Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(7), P. 3224 - 3252
Published: Jan. 1, 2024
Neoantigens
play
a
pivotal
role
in
the
field
of
tumour
therapy,
encompassing
stimulation
anti-tumour
immune
response
and
enhancement
targeting
capability.
Nonetheless,
numerous
factors
directly
influence
effectiveness
neoantigens
bolstering
responses,
including
neoantigen
quantity
specificity,
uptake
rates
by
antigen-presenting
cells
(APCs),
residence
duration
within
microenvironment
(TME),
their
ability
to
facilitate
maturation
APCs
for
activation.
Nanotechnology
assumes
significant
several
aspects,
facilitating
release,
promoting
delivery
cells,
augmenting
dendritic
shielding
from
protease
degradation,
optimizing
interactions
between
system.
Consequently,
development
nanotechnology
synergistically
enhances
efficacy
cancer
theranostics.
In
this
review,
we
provide
an
overview
sources,
mechanisms
neoantigen-induced
evolution
precision
neoantigen-based
nanomedicine.
This
encompasses
various
therapeutic
modalities,
such
as
immunotherapy,
phototherapy,
radiotherapy,
chemotherapy,
chemodynamic
other
strategies
tailored
augment
therapeutics.
We
also
discuss
current
challenges
prospects
application
nanomedicine,
aiming
expedite
its
clinical
translation.
RNA,
Journal Year:
2025,
Volume and Issue:
unknown, P. rna.080368.124 - rna.080368.124
Published: Jan. 7, 2025
Highly
recurrent
somatic
mutations
in
the
gene
encoding
core
splicing
factor
SF3B1
are
drivers
of
multiple
cancer
types.
is
a
scaffold
protein
that
orchestrates
multivalent
protein-protein
interactions
within
spliceosome
essential
for
recognizing
branchsite
(BS)
and
selecting
3’
splice
site
during
earliest
stage
pre-mRNA
splicing.
In
this
review,
we
first
describe
molecular
mechanism
by
which
oncogenic
disrupt
This
involves
perturbation
an
early
spliceosomal
trimeric
complex
necessary
accurate
BS
recognition
subset
introns,
leads
to
activation
upstream
branchpoints
selection
cryptic
sites.
We
next
discuss
how
specific
transcripts
affected
aberrant
SF3B1-mutant
cells
contribute
initiation
progression
cancer.
Finally,
highlight
prognostic
value
disease
phenotypes
different
cancer-associated
mutations,
critical
developing
new
targeted
therapeutics
against
cancers
still
lacking
clinic.
